These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7655134)

  • 41. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival after amphotericin B overdose treated with plasmapheresis.
    Wang GS; Banerji S; Roussil TK; Heard KJ
    Ann Pharmacother; 2013 Feb; 47(2):e9. PubMed ID: 23362040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions.
    Nicholl TA; Nimmo CR; Shepherd JD; Phillips P; Jewesson PJ
    Ann Pharmacother; 1995 Nov; 29(11):1081-7. PubMed ID: 8573948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.
    Caillot D; Chavanet P; Casasnovas O; Solary E; Zanetta G; Buisson M; Wagner O; Cuisenier B; Bonnin A; Camerlynck P
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):722-5. PubMed ID: 1425731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Open label, randomised, comparative phase III safety and efficacy study with conventional amphotericin B and liposomal amphotericin B in patients with systemic fungal infection.
    Bodhe PV; Kotwani RN; Kirodian BG; Kshirsagar NA; Pandya SK
    J Assoc Physicians India; 2002 May; 50(5):662-70. PubMed ID: 12186120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Administering amphotericin B--a practical approach.
    Khoo SH; Bond J; Denning DW
    J Antimicrob Chemother; 1994 Feb; 33(2):203-13. PubMed ID: 8182001
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experience with community-based amphotericin B infusion therapy.
    Malani PN; Depestel DD; Riddell J; Bickley S; Klein LR; Kauffman CA
    Pharmacotherapy; 2005 May; 25(5):690-7. PubMed ID: 15899731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective surveillance of intravenous amphotericin B use patterns.
    Grasela TH; Goodwin SD; Walawander MK; Cramer RL; Fuhs DW; Moriarty VP
    Pharmacotherapy; 1990; 10(5):341-8. PubMed ID: 2235670
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The influence of the duration of infusion on the acute toxicity of amphotericin B. Comparison of two hour versus four hour infusions].
    Arning M; Aul C; Dresen B; Schneider W
    Immun Infekt; 1991 Jun; 19(3):80-3. PubMed ID: 1916869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
    Caillot D; Reny G; Solary E; Casasnovas O; Chavanet P; Bonnotte B; Perello L; Dumas M; Entezam F; Guy H
    J Antimicrob Chemother; 1994 Mar; 33(3):603-13. PubMed ID: 8040124
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.
    Hamill RJ; Sobel JD; El-Sadr W; Johnson PC; Graybill JR; Javaly K; Barker DE
    Clin Infect Dis; 2010 Jul; 51(2):225-32. PubMed ID: 20536366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of Intralipid emulsions of amphotericin B.
    Herbrecht R; Letscher V
    J Antimicrob Chemother; 1997 Jul; 40(1):137-9. PubMed ID: 9249219
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
    Cagnoni PJ; Walsh TJ; Prendergast MM; Bodensteiner D; Hiemenz S; Greenberg RN; Arndt CA; Schuster M; Seibel N; Yeldandi V; Tong KB
    J Clin Oncol; 2000 Jun; 18(12):2476-83. PubMed ID: 10856108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.